Ampio Highlights Promising Ampion Data In Knee Osteoarthritis

Ampio Pharmaceuticals Inc AMPE announced data from the modified Intent-to-Treat (mITT) population in the AP-013 Phase 3 trial of Ampion in severe osteoarthritis of the knee (OAK).

  • The AP-013 study was designed to confirm the efficacy observed in the first pivotal trial, AP-003-A, and was powered to detect treatment differences between Ampion and saline control. 
  • In the mITT population (n = 618), which retained more than 85% power to evaluate improvements in pain, Ampion demonstrated a statistically significant reduction in pain and trended favorably toward improvement in function versus saline control. 
  • Further, the results in the Per Protocol efficacy population (n = 580), included in the original AP-013 statistical analysis plan, support these observations with a statistically significant reduction in pain and a statistically significant improvement in function versus saline control.
  • Also See: Ampio To Test Inhaled COVID-19 Treatment In India.
  • Ampio submitted a Type C meeting request to the FDA earlier this year. The agency will provide written responses to questions as the next step. 
  • The Company is on track to provide clarity on AP-013 by the end of 1H 2022.
  • Price Action: AMPE shares are up 8.31% at $0.54 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!